The Intelligence from The Economist
Wary pharma: AstraZeneca sours on UK
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Pharmaceutical giant AstraZeneca has paused a £200m investment in Britain and could move its primary listing to America. Can the UK maintain its status as a “life-science superpower”? Why autonomous air wings are the future of war in the sky. And how scientists in the Caribbean are restoring the barrier reef through “coral IVF”.
Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+
For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.
Hosted on Acast. See acast.com/privacy for more information.